CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance

[1]  Wang Er-bin.  Targeted therapy of renal cell carcinoma , 2006 .

[2]  Jonathan A. Cooper,et al.  Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. , 2004, Blood.

[3]  I. Bernstein,et al.  Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-γ1 in acute myeloid leukemia cells , 2004, Leukemia.

[4]  F. Mandelli,et al.  Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. , 2004, Blood.

[5]  M. Baccarani,et al.  First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. , 2004, Leukemia research.

[6]  E. Estey,et al.  Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. , 2004, Leukemia research.

[7]  L. Peterson,et al.  Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  I. Bernstein,et al.  The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. , 2004, Blood.

[9]  J. Dongen,et al.  High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients , 2004, Leukemia.

[10]  Boris Gorovits,et al.  Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. , 2004, Blood.

[11]  H. Kantarjian,et al.  New agents in acute myeloid leukemia and other myeloid disorders , 2004, Cancer.

[12]  J. Falkenburg,et al.  Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity , 2004, Leukemia.

[13]  C. Swanton.  Cell-cycle targeted therapies. , 2004, The Lancet. Oncology.

[14]  A. Hagemeijer,et al.  Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. , 2004, Haematologica.

[15]  M. Voso,et al.  In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study. , 2004, Haematologica.

[16]  A. Rohatiner,et al.  A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia , 2003 .

[17]  B. Dörken,et al.  Induction of apoptosis by enediyne antibiotic calicheamicin ϑII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner , 2003, Oncogene.

[18]  J. Armitage,et al.  Circulating CD20 and CD52 in patients with non‐Hodgkin's lymphoma or Hodgkin's disease , 2003, British journal of haematology.

[19]  E. Estey,et al.  Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia , 2003, Cancer.

[20]  E. Estey,et al.  Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. , 2003, Leukemia research.

[21]  G. Garcia-Manero,et al.  Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. , 2003, Leukemia research.

[22]  E. Estey,et al.  Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia , 2003, Cancer Chemotherapy and Pharmacology.

[23]  N. Osheroff,et al.  Activation of the DNA-Dependent Protein Kinase by Drug-Induced and Radiation-Induced DNA Strand Breaks , 2003, Radiation research.

[24]  B. Abbott.  ABCG2 (BCRP) expression in normal and malignant hematopoietic cells , 2003, Hematological oncology.

[25]  P. Richardson,et al.  Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. , 2003, Blood.

[26]  I. Bernstein,et al.  Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. , 2003, Blood.

[27]  P. Frost,et al.  Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. , 2003, Current opinion in pharmacology.

[28]  R. Fanin,et al.  Clinical characteristics, prognostic factors and multidrug‐resistance related protein expression in 36 adult patients with acute promyelocytic leukemia , 2003, European journal of haematology.

[29]  E. Erba,et al.  Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. , 2003, Blood.

[30]  W. Tissing,et al.  Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. , 2003, Blood.

[31]  R. Zhong,et al.  The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression. , 2003, Experimental hematology.

[32]  O. Hammarsten,et al.  Cleavage of cellular DNA by calicheamicin γ1 , 2003 .

[33]  松井 啓隆,et al.  Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers , 2003 .

[34]  H. Kantarjian,et al.  Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high‐risk myelodysplastic syndromes , 2003, Cancer.

[35]  M. Berger,et al.  A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma , 2003, Cancer Immunology, Immunotherapy.

[36]  D. Reinhardt,et al.  Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin , 2003, Leukemia.

[37]  D. Scheinberg,et al.  Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195 , 2003, Leukemia.

[38]  O. Hammarsten,et al.  Cleavage of cellular DNA by calicheamicin gamma1. , 2003, DNA repair.

[39]  D. Scheinberg,et al.  Immunotoxin resistance in multidrug resistant cells. , 2003, Cancer research.

[40]  P. Crocker,et al.  Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling. , 2002, Current opinion in structural biology.

[41]  H. Kantarjian,et al.  Differences in CD33 intensity between various myeloid neoplasms. , 2002, American journal of clinical pathology.

[42]  I. Bernstein,et al.  Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) , 2002, Leukemia.

[43]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[44]  A. Gewirtz,et al.  Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease , 2002, Bone Marrow Transplantation.

[45]  P. Thall,et al.  Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. , 2002, Blood.

[46]  E. Estey,et al.  Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. , 2002, Blood.

[47]  E. Rogakou,et al.  Histone H2A variants H2AX and H2AZ. , 2002, Current opinion in genetics & development.

[48]  G. McDonald,et al.  Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. , 2002, Blood.

[49]  P. Schultz,et al.  Transcriptional Effects of the Potent Enediyne Anti-Cancer Agent Calicheamicin γ1I , 2002 .

[50]  E. D. de Vries,et al.  The Role of Drug Efflux Pumps in Acute Myeloid Leukemia , 2002, Leukemia & lymphoma.

[51]  I. Bernstein,et al.  An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. , 2002, Bioconjugate chemistry.

[52]  P. Schultz,et al.  Transcriptional effects of the potent enediyne anti-cancer agent Calicheamicin gamma(I)(1). , 2002, Chemistry & biology.

[53]  Irwin Hollander,et al.  Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. , 2002, Bioconjugate chemistry.

[54]  P. Thall,et al.  Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. , 2001, Blood.

[55]  E. Ball,et al.  Direct effect of bispecific anti-CD33 x anti-CD64 antibody on proliferation and signaling in myeloid cells. , 2001, Leukemia research.

[56]  M. Berger,et al.  Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse , 2001, Journal of clinical pharmacology.

[57]  M. Berger,et al.  Impact of Age and Gender on the Pharmacokinetics of Gemtuzumab Ozogamicin , 2001, Pharmacotherapy.

[58]  I. Bernstein,et al.  Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. , 2001, Blood.

[59]  E. Estey,et al.  Mylotarg™ (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation , 2001, Cancer.

[60]  I. Bernstein,et al.  Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  X. H. Chen,et al.  Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  I. Bernstein,et al.  Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. , 2001, Blood.

[63]  内藤 健助.  Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines , 2001 .

[64]  K. Sankaranarayanan,et al.  Differential responses of Chinese hamster mutagen sensitive cell lines to low and high concentrations of calicheamicin and neocarzinostatin. , 2000, Mutation research.

[65]  M. Berger,et al.  Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676). , 2000 .

[66]  A. Neubauer,et al.  Characteristics and analysis of normal and leukemic stem cells: current concepts and future directions , 2000, Leukemia.

[67]  D. McVicar,et al.  Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. , 2000, Blood.

[68]  I. Bernstein.  Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate , 2000, Leukemia.

[69]  Matthew L. Thomas,et al.  The sialoadhesin CD33 is a myeloid‐specific inhibitory receptor , 1999, European journal of immunology.

[70]  F. Appelbaum,et al.  Antibody-targeted therapy for myeloid leukemia. , 1999, Seminars in hematology.

[71]  I. Bernstein,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate , 2017 .

[72]  C. Buckley,et al.  The Myeloid-specific Sialic Acid-binding Receptor, CD33, Associates with the Protein-tyrosine Phosphatases, SHP-1 and SHP-2* , 1999, The Journal of Biological Chemistry.

[73]  O. Legrand,et al.  Role of MRP1 in multidrug resistance in acute myeloid leukemia , 1999, Leukemia.

[74]  J. Downing,et al.  Acute myeloid leukemia. , 1999, The New England journal of medicine.

[75]  M. Czuczman,et al.  Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[76]  D. Scheinberg,et al.  Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[77]  A. Seelig.  How does P-glycoprotein recognize its substrates? , 1998, International journal of clinical pharmacology and therapeutics.

[78]  Margaret Gross-King.  For Acute Myelogenous Leukemia and Myelodysplastic Syndrome: This list of clinical research protocols relating to acute myelogenous leukemia and myelodysplastic syndrome is compiled for your convenience. , 1997 .

[79]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[80]  I. Bernstein,et al.  Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. , 1996, Cancer research.

[81]  B. J. Carter,et al.  Enediyne-mediated cleavage of RNA. , 1995, Bioorganic & medicinal chemistry.

[82]  P. Crocker,et al.  Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. , 1995, Blood.

[83]  M. Brenowitz,et al.  Salt dependence of calicheamicin-DNA site-specific interactions. , 1995, Biochemistry.

[84]  B. Kwon,et al.  A Study of the Reaction of Calicheamicin .gamma.1 with Glutathione in the Presence of Double-Stranded DNA , 1994 .

[85]  M. Andreeff,et al.  Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  D. Scheinberg,et al.  Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. , 1992, Cancer research.

[87]  I. Bernstein,et al.  THE USE OF RADIOLABELED ANTI‐CD33 ANTIBODY TO AUGMENT MARROW IRRADIATION PRIOR TO MARROW TRANSPLANTATION FOR ACUTE MYELOGENOUS LEUKEMIA , 1992, Transplantation.

[88]  S. Walker,et al.  Cleavage behavior of calicheamicin gamma 1 and calicheamicin T. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[89]  I. Bernstein,et al.  Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. , 1992, Cancer research.

[90]  D. Scheinberg,et al.  A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  L. Lyne,et al.  Sensitivity of fibroblasts derived from ataxia-telangiectasia patients to calicheamicin γ1I , 1990 .

[92]  A. Oronsky,et al.  Modulation of nicotinamide adenine dinucleotide and poly(adenosine diphosphoribose) metabolism by calicheamicin gamma 1 in human HL-60 cells. , 1990, Cancer letters.

[93]  G. Ellestad,et al.  Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. , 1988, Science.

[94]  M. Siegel,et al.  Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin .gamma.1I , 1987 .

[95]  I. Bernstein,et al.  Expression of normal myeloid-associated antigens by acute leukemia cells. , 1986, Blood.

[96]  J. Griffin,et al.  A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. , 1984, Leukemia research.

[97]  I. Bernstein,et al.  Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies , 1983 .